Associate Professor

Colm Keane

Email: 
Phone: 
+61 7 344 37912

Background

Dr Keane is a haematologist at Princess Alexandra Hospital and runs the Lymphoma Research Lab at the UQDI in Brisbane. His main research interest is focused on the interface between the tumour microenvironment and the malignant lymphoma cell, with a goal to build an understanding of lymphoma from an immunological and biomarkers perspective. To bridge developments between the clinic and bench-top, the laboratory has a strong emphasis on patient material, which it obtains from international and national clinical collaborators, much being from investigator-led clinical trials.

Lymphomas studied include more common lymphomas such as Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma and Follicular Lymphoma but his lab has a particular focus on rare lymphomas such as primary central nervous system lymphoma and lymphomas that develop in patients who are immunocompromised.

Dr. Keane has been instrumental in translating work from his lab into multiple immune based clinical trials currently being run across Australia, many in rare and hard to treat lymphomas, where patients have limited treatments available.

The goals of the lab are to directly improve outcomes for all lymphoma patients by performing innovative translational science that not only generates new knowledge and brings new treatments to Australian patients but helps to train the next generation of lymphoma researchers in Australia.

Availability

Associate Professor Colm Keane is:
Available for supervision

Qualifications

  • Masters (Coursework) of Business Administration, Griffith University
  • Doctor of Philosophy, Griffith University

Research interests

  • Tumour Immunology

  • DLBCL

  • Primary CNS Lymphoma

  • Hodgkin Lymphoma

  • Viral Associated Lymphomas

Search Professor Colm Keane’s works on UQ eSpace

116 works between 2004 and 2024
All (116) Journal Article (63) Book Chapter (1) Conference Publication (52)

41 - 60 of 116 works

2022

Journal Article

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

Gandhi, Maher K and Keane, Colm (2022). CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma. Haematologica, 108 (4), 1-3. doi: 10.3324/haematol.2022.281440

CD4 T Cells: the complicated key to unlocking the immune environment of classical Hodgkin Lymphoma

2022

Conference Publication

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study

Timmerman, John, Lavie, David, Johnson, Nathalie A., Avigdor, Abraham, Borchmann, Peter, Andreadis, Charalambos, Bazargan, Ali, Gregory, Gareth, Keane, Colm, Inna, Tzoran, Vucinic, Vladan, Zinzani, Pier Luigi, Zhang, Hong, Pillai, Pallavi, Marinello, Patricia and Herrera, Alex Francisco (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after anti-PD-1 treatment: An open-label phase 1/2 study

2022

Conference Publication

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

Johnson, Nathalie A., Lavie, David, Borchmann, Peter, Gregory, Gareth, Herrera, Alex Francisco, Minuk, Leonard, Vucinic, Vladan, Armand, Philippe, Avigdor, Abraham, Gasiorowski, Robin, Herishanu, Yair, Keane, Colm, Kuruvilla, John, Palcza, John, Pillai, Pallavi, Marinello, Patricia and Timmerman, John (2022). Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, Jun 03-07, 2022. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Favezelimab (anti-LAG-3) plus pembrolizumab in patients with anti-PD-1-naive relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL): An open-label phase 1/2 study

2021

Journal Article

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

Shanavas, Mohamed, Law, Soi‐Cheng, Hertzberg, Mark, Hicks, Rodney J., Seymour, John F., Li, Zhixiu, Merida de Long, Lilia, Nath, Karthik, Sabdia, Muhammed B., Gunawardana, Jay, Gandhi, Maher K. and Keane, Colm (2021). Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 10 (11) e1351, e1351. doi: 10.1002/cti2.1351

Intratumoral T‐cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large B‐cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (R‐CHOP) chemoimmunotherapy

2021

Journal Article

Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis

Keane, Colm, Coalter, Matthew and Martin-Loeches, Ignacio (2021). Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis. Frontiers in Medicine, 8 711397, 1-12. doi: 10.3389/fmed.2021.711397

Immune system disequilibrium-neutrophils, their extracellular traps, and COVID-19-induced sepsis

2021

Journal Article

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

Proctor, Martina, Gonzalez Cruz, Jazmina L., Daignault-Mill, Sheena M., Veitch, Margaret, Zeng, Bijun, Ehmann, Anna, Sabdia, Muhammed, Snell, Cameron, Keane, Colm, Dolcetti, Riccardo, Haass, Nikolas K., Wells, James W. and Gabrielli, Brian (2021). Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression. Cancers, 13 (15) 3733, 1-19. doi: 10.3390/cancers13153733

Targeting Replication Stress Using CHK1 Inhibitor Promotes Innate and NKT Cell Immune Responses and Tumour Regression

2021

Conference Publication

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

Manos, Kate, Khor, Richard, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew M., Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Hawkes, Eliza (2021). Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study. Annual Meeting of the American-Association-for-Cancer-Research (AACR), Philadelphia Pa, Apr 10-May 21, 2021. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study

2021

Journal Article

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

Nath, Karthik, Law, Soi-Cheng, Sabdia, Muhammed B., Gunawardana, Jay, de Long, Lilia M., Sester, David, Shanavas, Mohamed, Tsang, Hennes, Tobin, Joshua W. D., Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Jain, Sanjiv, Keane, Colm, Talaulikar, Dipti, Trotman, Judith, Law, Phillip and Gandhi, Maher K. (2021). Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 5 (12), 2644-2649. doi: 10.1182/bloodadvances.2020004051

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma

2021

Journal Article

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

Law, Soi C., Hoang, Thanh, O'Rourke, Kacey, Tobin, Joshua W. D., Gunawardana, Jay, Loo‐Oey, Dorothy, Bednarska, Karolina, Merida de Long, Lilia, Sabdia, Muhammed B., Hapgood, Greg, Blyth, Emily, Clancy, Leighton, Hennig, Stefanie, Keane, Colm and Gandhi, Maher K. (2021). Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells. American Journal of Transplantation, 21 (10) ajt.16628, 3465-3471. doi: 10.1111/ajt.16628

Successful treatment of Epstein–Barr virus–associated primary central nervous system lymphoma due to post‐transplantation lymphoproliferative disorder, with ibrutinib and third‐party Epstein–Barr virus–specific T cells

2021

Journal Article

PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma

Tobin, Joshua W. D., Bednarska, Karolina, Campbell, Ashlea and Keane, Colm (2021). PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma. Cells, 10 (5) 1152, 1-23. doi: 10.3390/cells10051152

PD-1 and LAG-3 checkpoint blockade: potential avenues for therapy in B-cell lymphoma

2021

Journal Article

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

Gandhi, Maher K., Hoang, Thanh, Law, Soi C., Brosda, Sandra, O'Rourke, Kacey, Tobin, Joshua W. D., Vari, Frank, Murigneux, Valentine, Fink, J. Lynn, Gunawardana, Jay, Gould, Clare M., Oey, Harald, Bednarska, Karolina, Delecluse, Susanne, Trappe, Ralf Ulrich, de Long, Lilia Merida, Sabdia, Muhammed Bilal, Bhagat, Govind, Hapgood, Greg, Blyth, Emily, Clancy, Leighton E., Wight, Joel, Hawkes, Eliza A., Rimsza, Lisa M., Maguire, Alanna, Bojarczuk, Kamil, Chapuy, Bjoern and Keane, Colm (2021). EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity. Blood, 137 (11), 1468-1477. doi: 10.1182/blood.2020008520

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity

2020

Conference Publication

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

Tsang, Hennes, Patch, Ann-Marie, Keane, Colm, Law, Soi C., Gunawardana, Jay, Blombery, Piers, Thompson, Ella R., Sabdia, Muhammed B., De Long, Lilia Merida, Belle, Clemence J., Nath, Karthik, Tobin, Joshua W.D., Kazakoff, Stephen H., Seymour, John F., MacManus, Michael and Gandhi, Maher K. (2020). Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma. 62nd ASH Annual Meeting and Exposition, Online, 5-8 December 2020. Washington, DC United States: American Society of Hematology. doi: 10.1182/blood-2020-135954

Neoantigens are typically associated with intact HLA class I presentation in early-stage follicular lymphoma

2020

Conference Publication

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study

Hawkes, Eliza Anne, Manos, Kate, Chong, Geoffrey, Palmer, Jodie, MacManus, Michael Patrick, Keane, Colm, Scott, Andrew Mark, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison Anne, Lee, Sze Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2020). Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Electr Network, May 29-31, 2020. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.

Phase I study of radiotherapy (RT) & durvalumab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL) & follicular lymphoma (FL): The RADD study

2020

Journal Article

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

Keane, Colm, Law, Soi C., Gould, Clare, Birch, Simone, Sabdia, Muhammed B., Merida de Long, Lilia, Thillaiyampalam, Gayathri, Abro, Emad, Tobin, Joshua W., Tan, Xiaohong, Xu-Monette, Zijun Y., Young, Ken H., Gifford, Grace, Gabreilli, Sara, Stevenson, William S., Gill, Anthony, Talaulikar, Dipti, Jain, Sanjiv, Hernandez, Annette, Halliday, Sarah-Jane, Bird, Robert, Cross, Donna, Hertzberg, Mark and Gandhi, Maher K. (2020). LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma. Blood Advances, 4 (7), 1367-1377. doi: 10.1182/bloodadvances.2019001390

LAG3: a novel immune checkpoint expressed by multiple lymphocyte subsets in diffuse large B-cell lymphoma

2020

Journal Article

Reply to M. Sorigue

Tobin, Joshua W.D., Keane, Colm, Gunawardana, Jay and Gandhi, Maher K. (2020). Reply to M. Sorigue. Journal of Clinical Oncology, 38 (6), 648-649. doi: 10.1200/JCO.19.02935

Reply to M. Sorigue

2019

Conference Publication

y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

Hawkes, Eliza A., Manos, Kate, Chong, Geoff, Palmer, Jodie, MacManus, Michael, Keane, Colm, Scott, Andrew, Shortt, Jake, Ritchie, David, Churilov, Leonid, Johnston, Laura, Witkowski, Tom, Barraclough, Allison, Lee, Sze-Ting, Lin, Wendi, Koldej, Rachel and Khor, Richard (2019). y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL USA, 7-10 December 2019. Washington, DC USA: American Society of Hematology. doi: 10.1182/blood-2019-122635

y Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): The RaDD Study

2019

Conference Publication

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

Nath, Karthik, Law, Soi C., Sabdia, Muhammed B., De Long, Lilia Merida, Shanavas, Mohamed, Tobin, Joshua W. D., Gunawardana, Jay, Vari, Frank, Halliday, Sarah-Jane, Hernandez, Annette, Cross, Donna, Bird, Robert J., Keane, Colm and Gandhi, Maher K. (2019). Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade. 61st Annual Meeting and Exposition of the American-Society-of-Hematology (ASH), Orlando, FL, United States, 7 - 10 December 2019. Washington, DC, United States: American Society of Hematology. doi: 10.1182/blood-2019-130050

Intra-tumoral CD8+T-cells in follicular lymphoma contain large clonal expansions that are amenable to dual-checkpoint blockade

2019

Journal Article

EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2

Cristino, Alexandre S., Nourse, Jamie, West, Rachael A., Sabdia, Muhammed Bilal, Law, Soi C., Gunawardana, Jay, Vari, Frank, Mujaj, Sally, Thillaiyampalam, Gayathri, Snell, Cameron, Gough, Madeline, Keane, Colm and Gandhi, Maher K. (2019). EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2. Blood, 134 (25), 2261-2270. doi: 10.1182/blood.2019000889

EBV-microRNA-BHRF1-2-5p targets the 3'UTR of immune-checkpoint ligands PD-L1 and PD-L2

2019

Journal Article

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance

Wight, Joel C., Yue, Mimi, Keane, Colm, Johnston, Anna, Linton, Kim, Chin, Collin, Wai, Shin Hnin, Talaulikar, Dipti, Gasiorowski, Robin, Yoon Cheah, Chan, Gregory, Gareth P., Dickinson, Michael, Minson, Adrian, Coombes, Caitlin, Ku, Matthew, Lam, Stephanie and Hawkes, Eliza A. (2019). Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance. British Journal of Haematology, 187 (2) bjh.16064, 174-184. doi: 10.1111/bjh.16064

Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance

2019

Journal Article

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

Keane, Colm, Tobin, Joshua, Gunawardana, Jay, Francis, Santiyagu, Gifford, Grace, Gabrielli, Sara, Gill, Anthony, Stevenson, William, Talaulikar, Dipti, Gould, Clare, Jain, Sanjiv, Birch, Simone, Hertzberg, Mark and Gandhi, Maher K. (2019). The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma. European Journal of Haematology, 103 (3) ejh.13274, 200-207. doi: 10.1111/ejh.13274

The tumour microenvironment is immuno‐tolerogenic and a principal determinant of patient outcome in EBV‐positive diffuse large B‐cell lymphoma

Current funding

  • 2022 - 2027
    An early phase, open label, multi-centre trial of front-line TheRapy for EBv-associated Lymphomas -- 2: TREBL-2 (Stream 6)
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2021 - 2024
    ALLGNHL32 Study - An ALLG Phase II study of pembrolizumab checkpoint blockade following chemoimmunotherapy for primary central nervous system lymphoma
    Australasian Leukaemia & Lymphoma Group
    Open grant
  • 2021 - 2026
    Investigation of Immune evasion in relapsed lymphoma (RADD Trial) (Victorian Cancer Agency Translational Research Project administered by La Trobe University)
    Olivia Newton-John Cancer Research Institute
    Open grant
  • 2021 - 2025
    Employing rational novel agent combination therapy to improve transplant cure rates for relapsed/refractory Hodgkin Lymphoma (MRFF RCRDUN administered by La Trobe University)
    La Trobe University
    Open grant
  • 2021 - 2025
    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma
    NHMRC MRFF Investigator Grant
    Open grant
  • 2019 - 2025
    An Open Label, Multicentre, Phase One Study Incorporating Early Application of CAR T cells for Primary Refractory Aggressive Lymphoma
    NHMRC MRFF - Rare Cancers, Rare Diseases and Unmet Need
    Open grant
  • 2018 - 2024
    An Open label, Multicentre, Phase I study of Ibrutinib, Rituximab and EBV specific T-cells in Patients with EBV-positive Primary or Secondary CNS Lymphoma unsuitable for standard therapies
    NHMRC MRFF - Lifting Clinical Trials Registries Capacity
    Open grant

Past funding

  • 2020 - 2023
    Novel immune based approaches to improve survival for patients with Primary Central Nervous Lymphoma
    Queensland Advancing Clinical Research Fellowship
    Open grant
  • 2019 - 2020
    Investigation of the key immuno-genetic drivers of Primary Central Nervous System Lymphoma that occurs in patients with HIV infection
    Cancer Australia
    Open grant
  • 2017 - 2020
    Investigation of unique immune microenvironment of Primary CNS Lymphoma
    NHMRC Early Career Fellowships
    Open grant
  • 2017 - 2019
    The prognostic utility of the tumour microenvironment in Non-Hodgkin's Lymphoma
    Celgene Pty Ltd
    Open grant
  • 2016 - 2017
    Does lymphoma avoid immune destruction by inducing T-cell tolerance?
    Cancer Council Queensland
    Open grant
  • 2015 - 2018
    A correlative laboratory study of primary CNS lymphoma
    Research Donation Generic
    Open grant
  • 2015 - 2018
    Net tumoral immunity and its impact on outcome in lymphoma
    The Leukaemia Foundation of Australia Limited
    Open grant

Availability

Associate Professor Colm Keane is:
Available for supervision

Before you email them, read our advice on how to contact a supervisor.

Supervision history

Current supervision

  • Doctor Philosophy

    Immuno-genetic biomarkers of response in a prospective study of immune checkpoint therapy in primary CNS lymphoma

    Principal Advisor

    Other advisors: Dr Arutha Kulasinghe, Dr Zachary Hawula

  • Doctor Philosophy

    Investigating the mechanisms of immune evasion in relapsed/refractory DLBCL

    Principal Advisor

    Other advisors: Dr Zachary Hawula

  • Doctor Philosophy

    Investigation of immune responses to novel and standard therapies in DLBCL

    Principal Advisor

    Other advisors: Dr Joshua Tobin, Associate Professor Fernando Guimaraes

  • Doctor Philosophy

    Impact of genetics upon the tumour microenvironment in Follicular Lymphoma

    Associate Advisor

    Other advisors: Dr Joshua Tobin, Dr Soi Law, Professor Maher Gandhi

  • Master Philosophy

    Amyloidosis Monitoring and Outcomes in an Australian Tertiary Centre

    Associate Advisor

  • Doctor Philosophy

    Reversing tumour necrosis factor-mediated immunosuppression to boost immunity against experimental CD19+ blood cancers

    Associate Advisor

    Other advisors: Dr Allie Lam, Associate Professor Fernando Guimaraes

Completed supervision

Enquiries

For media enquiries about Associate Professor Colm Keane's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au